Last reviewed · How we verify
Eicosapentaenoic acid ethyl ester
Eicosapentaenoic acid ethyl ester is an omega-3 polyunsaturated fatty acid that reduces triglyceride levels and modulates lipid metabolism.
Eicosapentaenoic acid ethyl ester is an omega-3 polyunsaturated fatty acid that reduces triglyceride levels and modulates lipid metabolism. Used for Hypertriglyceridemia, Cardiovascular disease prevention.
At a glance
| Generic name | Eicosapentaenoic acid ethyl ester |
|---|---|
| Also known as | EPADEL S900 TM (EPA ethyl ester, purity >98%) |
| Sponsor | Yamaguchi University Hospital |
| Drug class | Omega-3 fatty acid / Triglyceride-lowering agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
EPA ethyl ester is a purified form of eicosapentaenoic acid (EPA), an omega-3 fatty acid that acts as a substrate for anti-inflammatory mediators and reduces hepatic triglyceride synthesis. It lowers circulating triglycerides and may improve endothelial function and reduce cardiovascular inflammation through multiple lipid and inflammatory pathways.
Approved indications
- Hypertriglyceridemia
- Cardiovascular disease prevention
Common side effects
- Gastrointestinal upset
- Bleeding or bruising
- Fishy aftertaste
Key clinical trials
- IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion (PHASE2)
- Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (PHASE1, PHASE2)
- The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism (NA)
- EPA for Metastasis Trial 2 (PHASE3)
- Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (PHASE4)
- CreNeuroS™️CNS Fish Oil Plus Softgels Compared to Vascepa® Capsules and Deplin® Capsules in a Pharmacokinetic, Single Dose Evaluation on Healthy Adult Human Subjects Under Fasting Conditions (NA)
- Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk Cardiovascular Disease. (NA)
- Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eicosapentaenoic acid ethyl ester CI brief — competitive landscape report
- Eicosapentaenoic acid ethyl ester updates RSS · CI watch RSS
- Yamaguchi University Hospital portfolio CI